April 17, 2008 - Medivation, Inc. (Nasdaq: MDVN) announced that Alzheimer's patients treated with the investigational drug Dimebon(TM) showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in not only memory and language, but also in more complex functions such as awareness of time and place, and praxis -- the process of getting an idea and initiating and completing a new motor task. These clinical results were generated during a pivotal trial of Dimebon in patients with mild-to-moderate Alzheimer's disease (AD)... Medivation's Press Release -
Friday, April 25, 2008
Medivation : Dimebon Improves Significantly Thinking and Memory in Alzheimer's Disease Patients Over One Year
April 17, 2008 - Medivation, Inc. (Nasdaq: MDVN) announced that Alzheimer's patients treated with the investigational drug Dimebon(TM) showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in not only memory and language, but also in more complex functions such as awareness of time and place, and praxis -- the process of getting an idea and initiating and completing a new motor task. These clinical results were generated during a pivotal trial of Dimebon in patients with mild-to-moderate Alzheimer's disease (AD)... Medivation's Press Release -
